Clarity Pharmaceuticals (ASX:CU6) combined trastuzumab with its proprietary copper-chelating, or SAR, technology for the development of copper-67-based radioimmunotherapy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, according to a Tuesday Australian bourse filing.
Preclinical evidence showed a dose-response reduction in tumor size and prolonged survival using copper-67-SAR-trastuzumab compared to trastuzumab, an antibody that targets HER2, alone in a HER2-positive tumor mouse model, the filing said.
The firm collaborated with the University of Melbourne for the combination of the trastuzumab antibody with the SAR chelator and radiolabeling with copper-64 for diagnostic imaging, the filing added.
The firm plans to conduct a phase 1/2a theranostic study with copper-64 and copper-67 SAR trastuzumab in HER2-positive breast cancer patients, per the filing.
It also signed a supply agreement with EirGenix for the clinical development and future commercial supply of clinical-grade good manufacturing practice trastuzumab biosimilar, EG12014.
Its shares fell 6% in early trading on Tuesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。